首页> 外文期刊>Human Pathology: Case Reports >An atypical case of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-associated renal cell carcinoma identified by next-generation sequencing
【24h】

An atypical case of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-associated renal cell carcinoma identified by next-generation sequencing

机译:通过下一代测序鉴定出遗传性平滑肌瘤病和肾细胞癌(HLRCC)相关的非典型病例

获取原文
           

摘要

Germline mutations in the fumarate hydratase ( FH ) gene classically lead to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome. Patients with HLRCC typically exhibit multiple cutaneous and uterine leiomyomas at a young age. They also display a 20–30% lifetime risk for renal carcinomas, which commonly present before 40years of age, have a distinct papillary morphology, and an aggressive phenotype. However, the clinical presentation of HLRCC and the morphology of HLRCC-associated renal cell carcinomas (RCCs) can be variable and thereby evade diagnosis. Here, we present two cases of HLRCC-associated RCC to emphasize this point. The first case is typical of HLRCC, involving a 29-year-old man with multiple cutaneous leiomyomas and a renal tumor with characteristic papillary morphology. Next, we describe a 48-year-old man presenting with metastatic cancer of unknown primary origin and no skin findings. Interestingly, next-generation sequencing of his metastatic tumor identified two unique FH mutations. In both cases, FH mutations were confirmed as germline. These cases highlight the variable presentations of HLRCC-associated RCC and underscore the importance of screening tumors of unknown origin for FH mutations using next-generation sequencing.
机译:富马酸酯水合酶(FH)基因中的种系突变通常导致遗传性平滑肌瘤病和肾细胞癌(HLRCC)综合征。 HLRCC患者通常在年轻时会出现多发性皮肤和子宫平滑肌瘤。他们还显示出肾癌的终生风险为20–30%,肾癌通常在40岁之前出现,具有独特的乳头状形态和侵略性表型。但是,HLRCC的临床表现和与HLRCC相关的肾细胞癌(RCC)的形态可能会发生变化,从而逃避了诊断。在这里,我们提出两种与HLRCC相关的RCC的案例以强调这一点。第一例是典型的HLRCC,涉及一名29岁的男性,患有多发性皮肤平滑肌瘤和具有特征性乳头状形态的肾肿瘤。接下来,我们描述了一个48岁的男性,患有原发性未知且无皮肤发现的转移性癌症。有趣的是,他的转移性肿瘤的下一代测序确定了两个独特的FH突变。在这两种情况下,FH突变均被确认为种系。这些案例强调了与HLRCC相关的RCC的可变表现,并强调了使用下一代测序技术筛查FH突变来源不明的肿瘤的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号